Drug fused to antibody shrinks triple negative breast tumours

Anne Li                                                                                                March 18th, 2017


A drug that uses an antibody to target cancer cells shrank tumours in women with triple negative breast cancer that has spread, according to a small clinical trial. The study , run by Massachusetts General Hospital Cancer Center in the US, used a drug made by fusing a chemotherapy treatment to an antibody that targets Trop-2, a molecule found at high levels on the surface of many cancer cells. Published in the Journal of Clinical Oncology, the study found that tumours shrank by 30% or more in 21 of the 69 women given the drug. Two patients saw their tumours disappear completely. Almost 7 in 10 participants (70%) saw their tumours shrink to some extent, survival was on average 16.6 months. Professor Aditya Bardia, who led the study, said the results could lead to a new treatment option for this hard-to-treat cancer.


See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-03-15-drug-fused-to-antibody-shrinks-triple-negative-breast-tumours

Post a comment